IMVT
Immunovant, Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$29.17Close
$5.9BMarket cap
$22.02 – $44.9652-week range
Nov 9, 2026Next report · before the open
Highlights
Cautions
- Not in an uptrend 4 of 8 trend conditions
- Lagging the market RS 45 · weaker than 55% of stocks over 12 months
- Far from its high 35% below its 52-week high
- Distribution down-day volume 2.1× up-day volume over 50 sessions
- Results soon Nov 9, 2026, in 8 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
35%
1wk
up 2.7%
price change
1mo
down 13.6%
price change
12-month return
up 18%
market up 11% ·
its own up 24%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
7.0×
price / book
Earnings yield
down 10.0%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 65%
return on equity
Free cash margin
—
-$407.3M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
4.1%
$1.18 a day · 2×ATR $26.80
RS
45 / 99
vs the universe
Trend
4 / 8
trend template
Relative volume
0.8×
vs 50-day average
Up/down volume
0.48
50 sessions
Implied move
—
no option chain · report Nov 9, 2026
Contractions
2
29% → 24%
Pivot
$34.60
15.7% below
Volume dry-up
0.9×
10 vs 50 sessions
Trend template · 4 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: passes
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 19.9% over the year, from 170m to 204m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 6, 2026
Results reaction
Aug 6, 2026+1% vs market2 sessions after results
Financials
- Cash
- Long-term debt
| FY2021Mar 31, 2021 | FY2022Mar 31, 2022 | FY2023Mar 31, 2023 | FY2024Mar 31, 2024 | FY2025Mar 31, 2025 | FY2026Mar 31, 2026 | |
|---|---|---|---|---|---|---|
| Net income | -$107.4M | -$156.7M | -$211.0M | -$259.3M | -$413.8M | -$505.6M |
| Earnings per share | -$1.22 | -$1.43 | -$1.71 | -$1.88 | -$2.73 | -$2.77 |
| Free cash flow | -$83.5M | -$106.4M | -$188.4M | -$214.6M | -$376.6M | -$407.3M |
| Cash | $400.1M | $493.8M | $376.5M | $635.4M | $714.0M | $902.1M |
| Shareholders' equity | $391.5M | $469.8M | $362.5M | $617.8M | $707.4M | $852.6M |
| Shares outstanding | 97.97m | 116.48m | 130.33m | 145.58m | 170.11m | 203.94m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 20, 2026 | Annual ↗ | Mar 31, 2026 | 50d |
| Feb 6, 2026 | Quarterly ↗ | Dec 31, 2025 | 37d |
| Nov 10, 2025 | Quarterly ↗ | Sep 30, 2025 | 41d |
| Aug 11, 2025 | Quarterly ↗ | Jun 30, 2025 | 42d |
| May 29, 2025 | Annual ↗ | Mar 31, 2025 | 59d |
| Feb 6, 2025 | Quarterly ↗ | Dec 31, 2024 | 37d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 6, 2024 | Quarterly ↗ | Jun 30, 2024 | 37d |
| May 29, 2024 | Annual ↗ | Mar 31, 2024 | 59d |
| Feb 12, 2024 | Quarterly ↗ | Dec 31, 2023 | 43d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 3, 2026 | Shareholder vote ↗ |
| Aug 6, 2026 | Results ↗ |
| May 20, 2026 | Results ↗ |
| Feb 6, 2026 | Results ↗ |
| Dec 12, 2025 | Other events ↗ |
| Dec 11, 2025 | Other events ↗ |
| Nov 21, 2025 | Director or officer change ↗ |
| Nov 10, 2025 | Results ↗ |
| Sep 3, 2025 | Regulation FD · Other events ↗ |
| Aug 28, 2025 | Shareholder vote ↗ |
| Aug 11, 2025 | Results ↗ |
| Jul 29, 2025 | Director or officer change ↗ |